 | |
| Clinical data | |
|---|---|
| Routes of administration | unknown |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.073.052 |
| Chemical and physical data | |
| Formula | C22H20FN3OS |
| Molar mass | 393.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Tifluadom is abenzodiazepine derivative with an unusual activity profile.[1] Unlike most benzodiazepines, tifluadom has no activity at theGABAA receptor, but instead is a selectiveagonist for theκ-opioid receptor.[2] It has potentanalgesic[3] anddiuretic[4] effects in animals, and also hassedative effects and stimulatesappetite.[5][6]
While tifluadom has several effects which might have potential uses in medicine, such as analgesia and appetite stimulation, κ-opioid agonists tend to produce undesirable effects in humans such asdysphoria andhallucinations, and so these drugs tend to only be used inscientific research. Dysphoric effects are similar to those seen when using other κ-opioid receptor agonists likepentazocine andsalvinorin A, and can be considered the opposite of morphine-induced euphoria. As such, kappa agonists are believed to have very limited abuse potential.